[PDF] Top 20 Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment: an efficacy–tolerability pilot study
Has 10000 "Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment: an efficacy–tolerability pilot study" found on our website. Below are the top 20 most common "Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment: an efficacy–tolerability pilot study".
Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment: an efficacy–tolerability pilot study
... In patients who had previously received weak opioids, the starting OXN-PR dose was determined using conventional conversion tables for opioid ...All patients received their first OXN-PR tablet at 8 ... See full document
11
Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation
... present study adds further evidence to the fact that older patients with pain inadequately controlled by Step I analgesics of the WHO ladder and naive to opioids can be safely switched to ... See full document
9
Efficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patients
... 147 patients aged 70 years suffering from chronic pain (duration 3 months) of various nononcologic etiologies and of moderate- to-severe intensity (NRS score 4) despite analgesic treatment were ... See full document
11
Long-term efficacy and safety of oxycodone–naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study
... Fifty patients completed the ...of patients at T4 and 96% at T52 (P,0.0001). Pain intensity, measured on a 0–10 numerical rating scale, decreased from ...daily dose of oxycodone ... See full document
9
Is oxycodone/naloxone effective and safe in managing chronic pain of a fragile elderly patient with multiple skin ulcers of the lower limbs? A case report<div> </div>
... of pain on daily activities according to the Brief Pain Inventory (BPI) of both severity and interference domains, cognitive function using the Mini Mental State Examination (MMSE), and functional ... See full document
5
<p>Tapentadol: an overview of the safety profile</p>
... Abstract: Long-term opioid therapy may be associated with analgesic ef fi cacy and also pre- dictable adverse events, including cardiovascular and pulmonary events, gastrointestinal disorders, endocrinological harms, ... See full document
8
Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice
... and patients were aware of the study medication but were blinded to the study end ...open-label dose adjustments, use of concomitant medica- tions for opioid side effects as needed) with ... See full document
13
Progressive Change in Joint Degeneration in Patients with Knee or Hip Osteoarthritis Treated with Fentanyl in a Randomized Trial
... factors. Patients were random- ized 1:1:1 to the loxoprofen group, the tramadol/acetamino- phen group, or the transdermal fentanyl ...The dose of loxoprofen sodium was 60 mg three times per day, or a to- ... See full document
7
Effectiveness and safety of oxycodone/naloxone in the management of chronic pain in patients with systemic sclerosis with recurrent digital ulcers: two case reports
... in patients with non-SSc, and the GI tolerability of OXN-PR was ...both patients, pain relief was reached with the initial low dose ... See full document
5
Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone
... this study include that it is a post hoc analysis based on data gathered electronically from a large, prospective, randomized, controlled, Phase III clinical study; the sample size of this cohort of ... See full document
9
Restless legs syndrome: a new entity of neuropathic pain? Treatment with prolonged release oxycodone/naloxone combination
... responder patients, possibly based on the characteriza- tion of specific RLS ...from pain medicine, 13 as the sensory profile could represent a predictive ... See full document
5
Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids
... for pain intensity, pain-related disabilities in daily life activities/functionality, and ...QoL. Pain-intensity measures based on the LBP inten- sity index, which was calculated as arithmetic mean ... See full document
17
A customized home based computerized cognitive rehabilitation platform for patients with chronic stage stroke: study protocol for a randomized controlled trial
... A study researcher blinded to assessment procedure will perform the randomization of participants using the rand() function of Microsoft Excel software (Microsoft Excel 2010 for Windows), which is considered a ... See full document
10
Indiplon in the management of insomnia
... Abstract: Indiplon is a novel pyrazolopyrimidine, nonbenzodiazepine γ-aminobutyric acid (GABA) agonist studied for the treatment of insomnia. This article reviews the chemistry, pharmacology, clinical pharmacokinetics, ... See full document
12
Prolonged-release oxycodone/naloxone reduces opioid-induced constipation and improves quality of life in laxative-refractory patients: results of an observational study
... improve patients’ lives. Many of the patients in the study population had previ- ously failed laxatives, either because of lack of efficacy or because of intolerable side ...these ... See full document
11
Patient considerations in the use of tapentadol for moderate to severe pain
... the efficacy, tolerability, and safety of orally administered tapen- tadol ...in patients with moderate to severe pain due to chronic, painful DPN who tolerated tapentadol ER after ... See full document
9
A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain
... many patients still do not achieve adequate symptom relief, as they fail to address the underlying opioid-related ...18,19 Naloxone is a peripherally acting opioid antagonist with low systemic ... See full document
11
Considerations in selecting rapid-onset opioids for the management of breakthrough pain
... Breakthrough pain (BTP) is a transitory pain that occurs despite the use of long- term, around-the-clock ...on patients, their families, caregivers, and health-care ...The efficacy of ... See full document
12
Safety of opioids in osteoarthritis: Outcomes of a systematic review and meta-analysis
... of patients taking tramadol), which could limit its usefulness in clinical practice ...(hydromorphone, oxycodone) included in our study compared with placebo (RR ...improve tolerability and ... See full document
15
Analgesic effectiveness and tolerability of oral oxycodone/naloxone and pregabalin in patients with lung cancer and neuropathic pain: an observational analysis
... reported pain intensity was documented with the OXN-PR and pregabalin combination (API at T28 = ...in pain severity was already reported after 14 days (Figure 2). Mean pain intensity decrease at T28 ... See full document
10
Related subjects